TB-500: the thymosin-β4 fragment, explained

What TB-500 is — and the thymosin-β4 distinction

Thymosin beta-4 (Tβ4) is a naturally occurring 43-amino-acid protein involved in actin regulation, cell migration, angiogenesis and wound healing. TB-500 is not the same molecule. It is a shorter synthetic peptide corresponding to Tβ4's actin-binding region — the LKKTETQ motif, roughly residues 17–23. That 7-amino-acid motif is biologically meaningful (an isolated study showed it reproduced near-identical angiogenic activity to full Tβ4), but TB-500 lacks other functional domains the full protein has — for example the anti-inflammatory Ac-SDKP region near the N-terminus.

This distinction matters because marketing routinely conflates the two: claims drawn from thymosin-β4 research get attached to TB-500 the gray-market peptide, even though they are not identical and — critically — the human clinical trials were run on Tβ4, not on TB-500. It is also worth noting that "TB-500" sold as a research chemical is of unregulated identity and purity; what any given vial actually contains is not guaranteed.

What the evidence actually shows

Here is the honest version. The repair/recovery evidence is overwhelmingly rodent, in-vitro and veterinary — Tβ4 promotes angiogenesis, wound repair and hair-follicle development in animal models, and TB-500 has a long history of use (and doping detection) in racehorses. Those are the data that exist.

The parent protein Tβ4 has reached human Phase 2 trials — for dry-eye disease, dermal wound healing, and acute myocardial infarction — with some positive signals (and at least one program placed on a manufacturing-related clinical hold). But TB-500 itself has essentially no large human randomized controlled trials. Athletic recovery and injury claims for TB-500 are extrapolated from animal data and community observation, not controlled human evidence. The honest reading: TB-500 is investigational and unproven in humans, and the human data that does exist is about a related-but-different molecule.

The math

Because TB-500 ships (in the research market) as a lyophilized powder, any use involves reconstitution arithmetic — the same arithmetic the peptide reconstitution calculator does for any vial. Worked example, presented purely as arithmetic:

Concentration is just milligrams divided by millilitres, and units are just hundredths of a millilitre on a U-100 insulin syringe. Change the water volume and every number moves: the same 10 mg vial with 1 mL gives 10 mg/mL (so 2 mg = 20 units, a smaller draw). The reconstitution calculator converts vial size + water + target into exact syringe units (and works in reverse). The milligrams above are illustrative arithmetic, not a recommended dose — community protocols commonly report a twice-weekly ~2–2.5 mg loading phase then ~2 mg weekly, but no validated human dose exists.

Half-life & dosing pattern

Honest PK status: human pharmacokinetic data exist only for the full parent protein Tβ4, not for TB-500. In a healthy-volunteer study, intravenous Tβ4 had a short, dose-proportional half-life of roughly 1–2 hours. TB-500's own human PK is poorly characterized; animal estimates of a few hours circulate but are not well sourced.

Despite a short blood half-life, the community dosing pattern is infrequent — typically a twice-weekly loading phase (~2–2.5 mg) for a few weeks, then ~2 mg weekly — on the theory that tissue effects outlast blood levels. That theory is mechanistic inference, not measured human PK; treat it as unverified. You can still visualize how any half-life and interval accumulate in the half-life visualizer.

Storage & handling

• Lyophilized (powder, unreconstituted): kept frozen for long-term storage; freeze-dried peptide is the most stable form and is typically stored cold and away from light.
• Reconstituted (in bacteriostatic water): refrigerated at 2–8°C (36–46°F), not frozen — freeze/thaw cycles can damage peptide bonds. Reconstituted peptide is commonly used within about four weeks.
• Reconstitution technique: swab the stopper, add water slowly down the vial wall (not onto the powder), and swirl gently rather than shake until dissolved.
• Quality honesty: gray-market product may contain endotoxins, mis-sequenced peptide, or contaminants — unregulated manufacturing means identity, purity and sterility cannot be assumed. This is arguably the most concrete near-term hazard.

Stacking — the "Wolverine stack"

TB-500 is most commonly combined with BPC-157 in what the community calls the "Wolverine stack" for soft-tissue and recovery goals. This is community practice, not clinical guidance — there are no human trials of the combination, and both peptides are unapproved and WADA-banned. In OptiPin a stack like this is tracked as two separate compounds, each with its own schedule, dose log and vial inventory.

Tracking TB-500 in OptiPin

If you are tracking a recovery-peptide protocol, OptiPin treats it like any other entry — without endorsing it:

• Dose log + reminders — record each injection on a twice-weekly or weekly cadence and get reminded on the due day, with site rotation.
• Symptom & recovery tracking — log the specific outcome you care about over time so a trend lines up against actual dosing — the only honest way to judge an unproven compound on yourself.
• OptiInsight analysis — OptiPin's AI reads the full record (doses, symptoms, labs) and surfaces what moved with what.
• Vial & supply tracking — log the reconstituted vial; OptiPin estimates remaining volume, doses left, and an empty date.
• Built-in reconstitution math — the same calculator covered above is in the app, so the syringe-unit conversion is one tap.